Working to deliver functional improvement for people living with myotonic dystrophy

There are no approved therapies for myotonic dystrophy type 1 (DM1). Through the HARMONIA study, people living with DM1 have the opportunity to take part in research evaluating zeleciment basivarsen (DYNE-101), an investigational therapy being studied for its potential to make a meaningful difference.

Who can be in this study?

Participants in the HARMONIA study must:

- Be 16 years of age or older
- Have a diagnosis of DM1 confirmed by molecular genetics with trinucleotide repeat size greater than (>) 100. Historical results from clinical testing are acceptable
- Be able to walk 10 meters and complete 5 times sit to stand independently (inserts or supports that don't go above the ankle are allowed)
- Have a body mass index (BMI) less than (<) 35 kilograms per meter square (kg/m^2)
- Avoid becoming pregnant or fathering a child during the study
- Additional inclusion/exclusion criteria apply

HARMONIA

How long is this study?

Participation in the study could last approximately 18 months with participants receiving either zeleciment basivarsen (DYNE-101) or placebo for the first 48 weeks and all participants receiving only zeleciment basivarsen (DYNE-101) after 48 weeks on the study. However, being in this study is completely voluntary. Participants can leave at any time. Leaving the study will not affect the quality of the health care you receive.

Are there costs for participating?

Study treatment and all study tests and procedures are provided at no cost to study participants. Participants will be reimbursed for approved travel-related expenses. Concierge services to assist with arranging any travel, hotel and meals during study visits may be available to participants at no cost.



For more information, please contact:

URL: https://clinicaltrials.gov/study/NCT07486934

Email: clinicaltrials@dyne-tx.com